The PROTECT Survey Protocol was presented at the Fast Track Cities Conference in Amsterdam in September 2023. For more information, please see attached doc (PDF). 


Availability update

European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention

The European Commission (EC) has authorised Apretude (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention. Cabotegravir injection is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in high-risk adults and adolescents (at least 12 years of age), weighing at least 35 kg. The availability of cabotegravir LA for PrEP will differ from country to country across the EU. ViiV Healthcare are committed to working with respective regulatory authorities, governments, payors and other stakeholders to understand the local needs and make this product available to people who can benefit from this innovative prevention option.



The PROTECT survey will be available to complete in a select number of countries in Europe from October 2023.

Watch this space for more updates on the exact launch date and which countries will be participating first.


Journal article

Determinants of PrEP Uptake, Intention and Awareness in the Netherlands: A Socio-Spatial Analysis

Learn more about research into long acting injectable PrEP. Explore a recent article that explores determinants of PrEP Uptake, Intention and Awareness in the Netherlands.


Journal article

Spatio-temporal changes in pre-exposure prophylaxis uptake among MSM in mainland France between 2016 and 2021

This study used national pharmaco-epidemiology surveillance data and regional MSM population estimations to model the spatio-temporal distribution of PrEP uptake among MSM in France 2016–2021 to identify marginalized MSM at risk for HIV and increase their PrEP uptake.